Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
FOLR1 ( Folate receptor alpha )
i
Other names:
FOLR1, Folate Receptor Alpha, Ovarian Tumor-Associated Antigen MOv18, Adult Folate-Binding Protein, Folate Receptor 1 (Adult), Folate Receptor, Adult, Folate Receptor 1, KB Cells FBP, FR-Alpha, FOLR, FBP, Folate Binding Protein, FRalpha
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2348
Related tests:
‹
VENTANA FOLR1 RxDx Assay (5)
VENTANA FOLR1 RxDx Assay (5)
›
Associations
(33)
News
Trials
VERI cancer hierarchy
Reset Filters
FOLR1 positive
Ovarian Cancer
FOLR1 positive
Ovarian Cancer
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A1
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A1
FOLR1 positive
Peritoneal Cancer
FOLR1 positive
Peritoneal Cancer
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
mirvetuximab soravtansine-gynx
Sensitive
:
A1
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
mirvetuximab soravtansine-gynx
Sensitive
:
A1
FOLR1 positive
Fallopian Tube Cancer
FOLR1 positive
Fallopian Tube Cancer
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
mirvetuximab soravtansine-gynx
Sensitive
:
A1
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
mirvetuximab soravtansine-gynx
Sensitive
:
A1
FOLR1 positive
Ovarian Cancer
FOLR1 positive
Ovarian Cancer
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
mirvetuximab soravtansine-gynx
Sensitive
:
A1
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
mirvetuximab soravtansine-gynx
Sensitive
:
A1
FOLR1 expression
Ovarian Cancer
FOLR1 expression
Ovarian Cancer
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Ovarian Cancer
FOLR1 expression
Ovarian Cancer
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Fallopian Tube Cancer
FOLR1 expression
Fallopian Tube Cancer
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Peritoneal Cancer
FOLR1 expression
Peritoneal Cancer
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Peritoneal Cancer
FOLR1 expression
Peritoneal Cancer
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Fallopian Tube Cancer
FOLR1 expression
Fallopian Tube Cancer
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 overexpression
Ovarian Cancer
FOLR1 overexpression
Ovarian Cancer
mirvetuximab soravtansine-gynx
Sensitive: B - Late Trials
mirvetuximab soravtansine-gynx
Sensitive
:
B
mirvetuximab soravtansine-gynx
Sensitive: B - Late Trials
mirvetuximab soravtansine-gynx
Sensitive
:
B
FOLR1 expression
Ovarian Cancer
FOLR1 expression
Ovarian Cancer
STRO-002
Sensitive: C2 – Inclusion Criteria
STRO-002
Sensitive
:
C2
STRO-002
Sensitive: C2 – Inclusion Criteria
STRO-002
Sensitive
:
C2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.